Celularity Inc (CELU)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $20.45M
Last updated: Nov 17, 2026 at 11:03 AM ET
Celularity Inc (CELU) Financials: Revenue, Profit and Cash Flow
Celularity reported revenue of $26.55M for the fiscal year ended Dec 31, 2025, down 51.0% from the year before. That year, net income was -$91.72M with a net margin of -345.4%, operating cash flow was -$13.25M and free cash flow was -$13.25M. The quarter ended Sep 30, 2026 had revenue of $5.43M and net income of $706.00K.
Revenue and Margins
Over the 7 years to Dec 2025, revenue grew from $17.55M, a compound annual rate of 6.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $26.55M | -51.0% | 24.4% | -230.9% | -345.4% |
| Dec 2024 | $54.22M | +138.1% | 72.4% | -70.7% | -106.8% |
| Dec 2023 | $22.77M | +26.7% | 29.7% | -335.9% | -862.0% |
| Dec 2022 | $17.98M | -15.7% | -9.4% | -142.4% | 79.0% |
| Dec 2021 | $21.34M | +49.4% | 54.8% | -511.2% | -469.3% |
| Dec 2020 | $14.28M | -32.5% | 65.5% | -1064.0% | -1458.4% |
| Dec 2019 | $21.15M | +20.5% | 70.1% | -1249.0% | -1001.9% |
| Dec 2018 | $17.55M | N/A | 62.7% | 0.0% | 0.0% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.55M | $54.22M | $22.77M | $17.98M | $21.34M | $14.28M | $21.15M | $17.55M |
| Cost of revenue | $20.07M | $14.99M | $16.02M | $19.66M | $9.65M | $4.93M | $6.32M | $6.55M |
| Gross profit | $6.48M | $39.23M | $6.75M | -$1.69M | $11.68M | $9.35M | $14.82M | $11.00M |
| Research and development | $15.03M | $17.39M | $30.46M | $78.36M | $88.35M | $52.71M | $46.05M | $29.06M |
| Operating income | -$61.31M | -$38.36M | -$76.48M | -$25.60M | -$109.06M | -$151.93M | -$264.13M | -$1.10K |
| Net income | -$91.72M | -$57.89M | -$196.29M | $14.19M | -$100.12M | -$208.23M | -$211.88M | -$1.10K |
| EBITDA | N/A | N/A | N/A | N/A | -$88.11M | N/A | -$70.98M | -$1.10K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.43M | $3.85M | $4.10M | $4.10M | $5.28M | $5.74M | $18.13M | $18.13M | $9.30M | $12.11M | $14.68M | $3.79M |
| Gross profit | $3.08M | $2.39M | -$3.27M | -$3.27M | $1.38M | $494.00K | $10.79M | $10.79M | $5.41M | $2.50M | $13.04M | $184.00K |
| Operating income | -$4.24M | -$10.13M | -$22.06M | -$22.06M | -$12.90M | -$15.86M | -$9.28M | -$9.47M | -$11.53M | $13.31M | -$7.38M | -$99.26M |
| Net income | $706.00K | $874.00K | -$24.36M | -$24.36M | -$23.08M | -$24.52M | -$13.29M | -$13.29M | -$16.10M | $9.55M | -$22.01M | -$93.88M |
Balance Sheet
As of Dec 2025, short-term debt of $14.00M exceeded cash and equivalents by $7.83M. Shareholder equity was negative, at -$38.06M, as total liabilities of $145.39M exceeded total assets of $107.33M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $107.33M | $132.68M | $143.89M | $401.07M | $414.13M | $431.01M | $521.50M | $24.71K |
| Current assets | $12.32M | $20.56M | $19.79M | $33.50M | $37.24M | $72.16M | $36.81M | $24.71K |
| Cash and equivalents | $6.17M | $738.00K | $227.00K | $13.97M | $37.24M | $54.31M | $28.13M | $24.71K |
| Total liabilities | $145.39M | $123.84M | $102.93M | $202.16M | $314.71M | $412.30M | $383.63M | $150.56K |
| Short-term debt | $14.00M | $6.36M | N/A | $37.60M | $3.05M | $3.01M | N/A | N/A |
| Long-term debt | N/A | $35.93M | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | -$38.06M | $8.84M | $40.96M | $198.90M | $99.42M | $18.71M | $137.86M | -$125.85K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $96.17M | $99.48M | $107.33M | $107.33M | $114.24M | $120.28M | $132.68M | $132.68M | $128.84M | $143.89M | $143.82M | $157.19M |
| Total liabilities | $131.70M | $134.74M | $145.39M | $145.39M | $134.33M | $145.78M | $123.84M | $123.84M | $111.56M | $102.93M | $112.57M | $126.94M |
| Cash and equivalents | $586.00K | $368.00K | $6.17M | $6.17M | $120.00K | $863.00K | $738.00K | $738.00K | $133.00K | $227.00K | $1.90M | $273.00K |
| Shareholder equity | -$35.53M | -$35.26M | -$38.06M | -$38.06M | -$20.09M | -$25.50M | $8.84M | $8.84M | $17.28M | $40.96M | $31.25M | $30.25M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.25M | -$6.40M | -$38.69M | -$137.88M | -$110.10M | -$63.19M | -$1.10M | -$543 |
| Capital expenditures | $0 | $161.00K | $4.05M | $5.24M | $6.20M | $27.83M | $3 | $1.92M |
| Free cash flow | -$13.25M | -$6.56M | -$42.73M | -$143.11M | -$116.30M | -$91.03M | -$1.10M | -$1.92M |
| Dividends paid | $5.90M | $0 | N/A | $39.07M | N/A | N/A | N/A | N/A |
| Investing cash flow | N/A | $514.00K | N/A | -$5.24M | -$5.90M | -$12.81M | -$286.85M | -$31.18M |
| Financing cash flow | $18.65M | $6.70M | $24.09M | $119.84M | $98.56M | $102.01M | $288.84M | $25.25K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.11M | $1.45M | -$5.10M | -$5.10M | -$4.16M | -$999.00K | $1.59M | $1.59M | -$144.00K | -$4.34M | -$4.40M | -$8.32M |
| Capital expenditures | $0 | $0 | $0 | $0 | $56.00K | $1 | $56.00K | $56.00K | $35.00K | $580.00K | $39.00K | $228.00K |
| Free cash flow | -$1.11M | $1.45M | -$5.10M | -$5.10M | -$4.21M | -$999.00K | $1.54M | $1.54M | -$179.00K | -$4.92M | -$4.44M | -$8.55M |
Frequently Asked Questions About CELU
What is Celularity's annual revenue?
Celularity reported revenue of $26.55M for the fiscal year ended Dec 31, 2025.
How fast is Celularity's revenue growing?
Revenue was down 51.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 13.9%.
Is Celularity profitable?
No. Celularity reported net income of -$91.72M for the fiscal year ended Dec 31, 2025, with a net margin of -345.4%.
How much free cash flow does CELU generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.25M minus capital expenditures of $0 produced free cash flow of -$13.25M.
How much debt does Celularity have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $14.00M and cash and equivalents of $6.17M.
CELU pages: Overview, Earnings, Financials, Competitors